TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Alere Named 2010 Innovator of the Year by Pegasystems (PR Newswire) Alere, one of the nation's top providers of integrated health and wellness programs to health plans and employers, was named 2010 Innovator of the Year by Pegasystems, a leader in business process management . us.rd.yahoo.com |
Amgen's 15-Year Effort to Build a Blockbuster Pays Off The Burrill Report submits: Amgen’s (AMGN) denosumab, its treatment for osteoporosis, has won approval in both Europe and the United States. Marketed under the name Prolia, analysts forecast sales will approach $1 billion in 2011 and EvaluatePharma thinks that could grow to $5.3 billion by 2016.We spoke to Dave Lacey, senior vice president and head of research for Amgen, about the long road travelled to bring Prolia to market, why the discovery and development of new drugs like it remains so difficult, and what other interesting therapies might be working their way through Amgen’s deep pipeline.Complete Story » seekingalpha.com |
Pharmacies Win California Ruling The California Supreme Court handed a legal victory to retail pharmacies that accuse drug makers of conspiring to set prices at artificially high levels. online.wsj.com |
Orexigen Signs Obesity-Drug Pact With Takeda Orexigen signed a North American partnership for its experimental obesity drug Contrave with Takeda Pharmaceutical. online.wsj.com |
Safety Concerns Weigh Heavily on Amag Pharma's Lead Product EP Vantage submits:Shares in Amag Pharmaceuticals (AMAG) have lost half their value since late July, driven to a four-year low on regulatory and safety news. The most dramatic fall came Tuesday from the company’s Monday announcement that it will not appear at an investor conference because of an upcoming FDA meeting over a cardiac safety signal in its lead product, Feraheme (ferumoxytol).For a product that took three tries to pass FDA muster, a new safety concern is a worrying sign, even more so after Amag was forced in February to respond to reports of hypersensitivity reactions; at the time the company noted the event rates were consistent with disclosures in the product labeling. This comes on top of looming changes to reimbursement at US kidney dialysis centers that may price Feraheme, an intravenous iron-replacement therapy for patients with chronic kidney disease (CKD), out of a key market.Complete Story » seekingalpha.com |